Abstract

Inspire Medical Systems will report its second-quarter 2026 results after the market close (Post Market) on August 03, 2026, with investor attention on revenue trajectory, margins, and EPS against a backdrop of reimbursement-driven volatility and updated guidance for the remainder of 2026.

Market Forecast

For the second quarter of 2026, the market projects revenue of 194.70 million US dollars, representing a year-over-year decrease of 9.15%, and adjusted EPS of -0.27, implying a year-over-year change of -231.78%; EBIT is estimated at -10.14 million US dollars with a year-over-year change of -656.31%. While consensus lacks explicit gross-margin and net-margin forecasts for the quarter, recent commentary points to a more conservative revenue cadence through mid-2026 as centers adapt to coding pathways. The core therapy system and procedure volumes remain the principal revenue engine; management previously reset the full-year 2026 revenue outlook to a range of 825.00 million to 875.00 million US dollars, framing a steadier second-half recovery as coding experience accumulates at implanting centers. The most promising near-term catalyst is the Inspire V platform’s continued adoption and mix benefits—although the company does not break out product-line revenue, total first-quarter revenue was 204.58 million US dollars, up 1.62% year over year, with the newer device contributing to gross-margin expansion.

Last Quarter Review

In the first quarter of 2026, Inspire Medical Systems reported revenue of 204.58 million US dollars (+1.62% year over year), a gross profit margin of 86.47%, a GAAP net loss attributable to shareholders of 11.29 million US dollars, a net profit margin of -5.52%, and adjusted EPS of -0.39 (-490.00% year over year). Operating cash flow improved to 12.80 million US dollars from cash usage a year earlier, and the gross margin expanded by approximately 1.8 percentage points as product mix shifted toward Inspire V. Main business highlight: overall revenue of 204.58 million US dollars grew 1.62% year over year despite the widened net loss, supported by procedure volumes and therapy system sales through the quarter.

Current Quarter Outlook

Core therapy system performance and reimbursement execution

The second quarter is set against a period of learning and adaptation at implanting centers, with coding and prior-authorization workflows remaining the dominant constraint on throughput. Management’s revised full-year revenue range of 825.00 million to 875.00 million US dollars indicates a more measured cadence in the middle of the year, and external commentary suggests the second quarter could represent a trough in growth as centers adapt to current codes. Within this context, the consensus revenue estimate of 194.70 million US dollars implies a sequential step-down from the first quarter, consistent with the guided soft patch. The near-term execution focus is on stabilizing prior-authorization submission volumes and reducing administrative friction so that scheduled procedures convert more reliably into implants. Pricing dynamics are not the primary headwind in the quarter; rather, procedural flow and reimbursement certainty are the key levers. If authorization rates stabilize and cycle times compress, the sales funnel can normalize in the second half, but the degree of improvement will depend on how quickly sites resolve practical coding issues. In parallel, management’s messaging around center readiness and scheduling visibility will matter for investor confidence, as it can corroborate or challenge the notion that the second quarter is indeed the low point in the revenue trajectory. The company’s first-quarter gross margin of 86.47% sets a constructive baseline for profitability if volume headwinds ease and product mix stays favorable. However, with consensus EPS at -0.27 and EBIT at -10.14 million US dollars for the second quarter, investors are bracing for operating deleverage in the short term. The bridge back to profitability will rely on restoring growth in procedures, leveraging fixed-cost infrastructure, and maintaining healthy average selling prices while avoiding incremental discounting to accelerate center adoption.

Inspire V adoption as a margin and growth catalyst

Inspire V contributed to the first quarter’s margin uptick, and its continued adoption is a central element of the medium-term operating thesis. As a newer-generation platform, its advantages can support sustained high gross margins once the procedural cadence normalizes, which is especially pertinent given the company’s first-quarter gross margin of 86.47%. While the market lacks a clean product-line revenue breakout, the qualitative impact is visible: the mix shift toward Inspire V helped expand gross margin by roughly 1.8 percentage points in the first quarter. Management and external analysis indicate that coding familiarity will improve with time; as this occurs, the paths for Inspire V procedures should streamline, thereby amplifying the platform’s contribution to revenue and margin. For the current quarter, investors will watch whether the planned second-quarter trough in growth corresponds with a rising share of Inspire V in the overall mix. If so, even a lighter revenue quarter could still demonstrate margin resilience and set up for a better operating profile in the second half. Given the consensus revenue forecast of 194.70 million US dollars (-9.15% year over year) and EPS of -0.27 (-231.78% year over year), the near-term financials reflect mix and volume uncertainty more than structural product economics. Confirmation that centers are refining workflows for Inspire V would help narrow the gap between revenue potential and realized output. It would also bolster confidence in the full-year range of 825.00 million to 875.00 million US dollars, where the back half must carry a larger share of growth.

Key stock-price swing factors this quarter

Reimbursement and coding clarity remain the dominant swing factor for the equity this quarter. External analysis has highlighted that consistent clarity on coding pathways is essential for center-level execution and the company’s near-term growth, with the lack of such clarity cited as a reason for a cautious stance from several institutions. Relatedly, prior-authorization volume trends are pivotal: commentary indicates submissions declined in the first quarter, with expectations that the second quarter is the trough given early signs of stabilization as centers gain coding experience. If data points on authorization inflows and cycle times improve, they could positively surprise sentiment even if the quarter’s absolute revenue is in line with the 194.70 million US dollars consensus. The second swing factor is the balance between operating spend and margin preservation. With an EBIT forecast of -10.14 million US dollars and EPS at -0.27 for the quarter, investors will scrutinize cost control and investment pacing—particularly commercial support for centers and training resources—against the need to protect long-term growth. Stronger cash conversion in the first quarter, with 12.80 million US dollars of operating cash flow, demonstrates that working-capital management can mitigate earnings variability; sustaining this discipline in a softer revenue quarter would be a positive signal. The third factor is guidance communication: reaffirming or tightening the 825.00 million to 875.00 million US dollars revenue range would help frame second-half expectations, while any shift to the lower end of the range might extend caution into the back half absent concrete signs of authorization recovery. Finally, investors will monitor qualitative commentary on patient behavior and scheduling dynamics at centers. Earlier headwinds have included patient deferrals and operational complexity; an update indicating improved throughput or better scheduling visibility would help de-risk the second half. Conversely, any incremental disruption—whether administrative or operational—could overshadow the product-driven margin advantages demonstrated in the first quarter. Against this backdrop, clear disclosure on authorization pipelines, scheduled implant volumes, and the product mix will be central to how the stock trades around the print and guidance.

Analyst Opinions

Across the research published since January 01, 2026, the ratio of bullish to bearish opinions skews negative, with approximately 2 bullish views versus 5 bearish views, while several additional firms have adopted neutral or “In Line/Hold” stances. The majority view is cautious to bearish, centered on reimbursement uncertainty and near-term revenue risk. Bank of America Securities downgraded the stock to Underperform with a 39.00 US dollars price target, arguing that the shares are unlikely to outperform without consistent clarity on coding pathways for centers and that estimate risks persist until an official, simplified coding framework removes procedural ambiguity. Evercore ISI reduced its stance to In Line and cut its price target to 40.00 US dollars, reflecting tempered expectations for growth and a belief that the balance of risks warrants a market-perform posture until authorization volumes and conversion rates stabilize. Piper Sandler moved to a neutral stance and lowered its target to 55.00 US dollars, signaling a more measured view on near-term execution despite acknowledging product advantages. RBC maintained a Hold view with a reduced target, consistent with the theme that the equity requires better visibility on reimbursement and flow dynamics before re-rating. Truist continues to rate the shares Hold with a target around the low- to mid-50s, emphasizing the need for proof points that the second-quarter slowdown is indeed a trough and that center workflows are normalizing. These bearish and cautious opinions converge on several analytics-driven pillars. First, the reset 2026 revenue range of 825.00 million to 875.00 million US dollars points to a softer mid-year and a heavier back-half lift; until prior-authorization inflows and scheduling conversion data confirm that trajectory, analysts expect volatility around quarterly results. Second, margin quality is viewed as structurally sound given the first quarter’s 86.47% gross margin and the favorable Inspire V mix, but consensus expects short-term operating deleverage with second-quarter EBIT estimated at -10.14 million US dollars and EPS at -0.27, leaving limited buffer if revenue undershoots. Third, institutions weigh the risk that timeline slippage in coding clarity could defer the anticipated rebound in throughput, arguing for a conservative risk-reward setup until evidence shows authorization pipelines improving and center operations running more smoothly. The minority, more constructive perspective—typified by Stifel’s maintained Buy ratings with targets in the mid-60 to 70 US dollars range—acknowledges these operational headwinds yet emphasizes the quality of the product platform and the potential for a back-half inflection as coding experience builds. However, given that the majority of recent institutional updates stress caution, the prevailing analytical framework focuses on watching for three things: stabilization in prior-authorization submissions and faster cycle times; sustained gross-margin strength from Inspire V mix even at subdued volumes; and guidance language that underwrites a higher-confidence second-half ramp. If these factors materialize in line with management’s commentary that the second quarter is the trough, analysts indicate that risk premia could compress; if not, the consensus leans toward maintaining a defensive stance and price targets clustered between 39.00 and 55.00 US dollars until operational clarity improves.